Anti-PD-1 or anti-PD-1/CTLA-4 treatment alone was not sufficient to achieve tumor regression in this model, possibly due to insufficient priming of T cells by myeloid CD206-DCs and/or the absence of dominant tumor antigens in this system. This evidence concerns the gene PDCD1 and neoplasm.